H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating, Maintains Target Price $25
CareDx Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $25 Price Target
CareDx: Balancing Growth and Challenges With a Hold Rating
Wells Fargo Maintains CareDx(CDNA.US) With Hold Rating, Cuts Target Price to $19
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating, Announces Target Price $40
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Cuts Target Price to $30
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
CareDx Analyst Ratings
Goldman Sachs Maintains CareDx(CDNA.US) With Buy Rating, Cuts Target Price to $26
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Maintains Target Price $35
BTIG Remains a Buy on CareDx (CDNA)
CareDx Is Maintained at Neutral by HC Wainwright & Co.
H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating, Cuts Target Price to $25
Wells Fargo Maintains CareDx(CDNA.US) With Hold Rating, Cuts Target Price to $23.5
CareDx Price Target Maintained With a $40.00/Share by Stephens & Co.
CareDx Analyst Ratings
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Maintains Target Price $35
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Kura Oncology (KURA) and CareDx (CDNA)
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating